Potential impact of serpin peptidase inhibitor clade (A) member 4 SERPINA4 (rs2093266) and SERPINA5 (rs1955656) genetic variants on COVID-19 induced acute kidney injury.

Background: SARS-CoV-2 has a number of targets, including the kidneys. Acute Kidney Injury (AKI) might develop in up to a quarter of SARS-CoV-2 patients. In the clinical environment, AKI is linked to a high rate of death and leads to the progression of AKI to chronic renal disease.

Aim: We aimed to investigate rs2093266 and rs1955656 polymorphisms in and genes, respectively, as risk factors for COVID-19 induced AKI.

Subjects And Methods: A case-control study included 227 participants who were divided into three groups: 81 healthy volunteers who served as controls, 76 COVID-19 patients without AKI and 70 COVID -19 patients with AKI. The TaqMan assay was used for genotyping the (rs2093266) and (rs1955656) polymorphisms by real-time PCR technique.

Results: Lymphocytes and eGFR showed a significantly decreasing trend across the three studied groups, while CRP, d-Dimer, ferritin, creatinine, KIM-1and NGAL showed a significantly increasing trend across the three studied groups ( < 0.001). Rs2093266 (AG and AA) genotypes were significant risk factors among non-AKI and AKI groups in comparison to controls. Rs1955656 (AG and AA) were significant risk factors among the AKI group, while AA was the only significant risk factor among the non-AKI group. Recessive, dominant, co-dominant, and over-dominant models for genotype combinations were demonstrated. The GG v AA, GG + AG v AA, and GG v AG + AA models of the rs2093266 were all significant predictors of AKI, whilst only the GG v AA model of the rs1955656 SNP was a significant predictor. The logistic regression model was statistically significant, 2 = 56.48,  < 0.001. AKI was associated with progressed age (OR = 0.95, 95% CI: 0.91-0.98,  = 0.006), suffering from chronic diseases (OR = 3.25, 95% CI: 1.31-8.01,  = 0.010), increased BMI (OR = 0.89, 95% CI: 0.81-0.98,  = 0.018), immunosuppressive (OR = 4.61, 95% CI: 1.24-17.16,  = 0.022) and rs2093266 (AG + AA) (OR = 3.0, 95% CI: 1.11-8.10,  = 0.030).

Conclusion: Single nucleotide polymorphisms (rs2093266) at gene and (rs1955656) at gene were strongly linked to the development of AKI in COVID-19 patients.